These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22261365)

  • 1. Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
    Dalamaga M; Archondakis S; Sotiropoulos G; Karmaniolas K; Pelekanos N; Papadavid E; Lekka A
    Maturitas; 2012 Mar; 71(3):301-8. PubMed ID: 22261365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters.
    Dalamaga M; Karmaniolas K; Papadavid E; Pelekanos N; Sotiropoulos G; Lekka A
    Menopause; 2011 Nov; 18(11):1198-204. PubMed ID: 21712732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters.
    Dalamaga M; Sotiropoulos G; Karmaniolas K; Pelekanos N; Papadavid E; Lekka A
    Clin Biochem; 2013 May; 46(7-8):584-90. PubMed ID: 23321342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer.
    Assiri AM; Kamel HF
    Obes Res Clin Pract; 2016; 10(4):442-53. PubMed ID: 26388139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperresistinemia is associated with postmenopausal breast cancer.
    Dalamaga M; Karmaniolas K; Papadavid E; Pelekanos N; Sotiropoulos G; Lekka A
    Menopause; 2013 Aug; 20(8):845-51. PubMed ID: 23481121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
    Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Level of CA 15-3 antigen--a prognostic factor in patients with breast cancer?].
    Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
    Przegl Lek; 1996; 53(11):788-92. PubMed ID: 9173440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
    Shering SG; Sherry F; McDermott EW; O'Higgins NJ; Duffy MJ
    Cancer; 1998 Dec; 83(12):2521-7. PubMed ID: 9874458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
    Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
    Dalamaga M
    Med Hypotheses; 2012 Nov; 79(5):617-21. PubMed ID: 22922056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone and biological characteristics of breast cancers in postmenopausal women.
    Secreto G; Venturelli E; Meneghini E; Greco M; Ferraris C; Gion M; Zancan M; Fabricio AS; Berrino F; Cavalleri A; Micheli A
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2942-8. PubMed ID: 19843675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women.
    Li XY; Tang SH; Zhou XC; Ye YH; Xu XQ; Li RZ
    Peptides; 2014 Jan; 51():86-90. PubMed ID: 24269296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
    Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
    Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment values of serum CA 15-3 antigen related to prognostic factors in breast cancer patients.
    Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
    Neoplasma; 1996; 43(4):225-9. PubMed ID: 8931745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.